Dasminapant (APG-1387) is a bivalent SMAC mimetic and inhibitor of apoptosis protein (IAP) antagonist provided for research use. It promotes degradation of cIAP-1 and XIAP, activates caspase-3, and induces apoptosis in preclinical cancer models, supporting studies in hepatocellular, ovarian, and nasopharyngeal carcinoma.
- Bivalent SMAC mimetic that antagonizes IAP family proteins.
- Promotes degradation of cIAP-1 and XIAP and triggers caspase activation.
- Used in preclinical studies of various solid tumors.
- High reported purity suitable for research applications.
- Available in small milligram pack sizes for experimental use.